higher growth deliv like come
rais pt
co post beat organ growth improv slightli
ahead rang unchang urolift grew cc deliv anoth
record vsi help drive cc growth across vascular access
higher sale drove ep beat despit higher spend ul/manta view
provid earli look new higher-growth remain well posit
out-perform year buy pt
sneak peek new growth profil take place among high-decil grower
organ growth improv last last year mix
balanc recent rolled-in neotract vsi legaci busi
particularli within intervent access within rolled-in bucket urolift ul
continu outperform contribut roughli increment growth
versu deliv last year intervent access grew cc despit
tough comp cc last year better perform sever vsi line biolog
micro-cathet guide-lin along resurg intra-aort balloon pump
iabp legaci busi latter co saw growth iabp
indic faster uptak consol introduc last year print coincid
miss point potenti follow-on tailwind
regain traction impella
margin soft telegraph spend new cost-out program cushion lrp target
adj om touch ahead expect actual despit sizabl
top-lin beat confluenc factor hit fx tariff cog inflat off-set
mix benefit ul vsi oper line look ahead co
commit addit spend ul marketing/japan regulatori effort
roll-out manta repres headwind margin despit co
re-affirmed adj om rang offset come mix shift
higher margin product line harvest restructur
cost save amount increment ep fulli complet
tweak rais pt still confid ep time
revis rev/ep go prior revis
prior reflect higher ul revis
prior intervent access revis new report
structur off-set slightli higher spend ul/manta revis model still
bake signific contribut manta repla repres sourc
upsid outsid ul ul acceler vsi rebound legaci provid healthi
contribut increas balanc sheet flexibl path adj ep
support upsid case time look achiev
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
buy thesi predic best-in-class report
organ top-lin growth profil rel peer
continu upsid adjust om restructur
balanc sheet flexibl support continu tuck-in
posit one better posit
mid-cap hospit suppli provid compani
increasingli attract larger diversifi med-tech peer
deep-div analysi neotract acquisit doc survey
along detail bottom-up analysi restructur
success bla trial clearanc repla
launch percuv manta
aua meet may
msd organ growth annual om
contribut urolift
limit market releas launch percuv manta
repla launch
follow-on deal similar scale neotract near-term
hsd organ growth annual om expans
contribut urolift
higher contribut percuv manta
repla
follow-on deal similar scale neotract near-term
bull case pt assum adj ep
lsd organ growth annual om expans
sub contribut urolift
deceler growth increas competit
delay market releas percuv manta repla
follow-on deal similar scale neotract rise debt
bear case pt use bear-cas ep
pleas see import disclosur inform page report
gener earn estim reflect cash ep calcul
financi summari market data
gener earn estim reflect cash ep calcul
estim valuat
pleas see import disclosur inform page report
urolift anoth strong us breadth expans
japan track
urolift grew contribut last
growth acceler come primarili new physician add bring total train
urologist us last start urolift
remain strong also look increasingli robust current lrp
strategi go deeper key account us continu pay dividend
eventu full-scal launch japan serv signific potenti sourc upsid
us penetr activ bph surgeon account hover around
last overal penetr remain around henc
runway core us market ul still expans beyond sale execut still
track launch mid-year full convers user-bas expect
new design carri substanti gm benefit versu
faster convers gate could drive upsid near-term
japan messag consist follow earlier-than-expect shonin clearanc
late last year co activ pursu reimburs target soft launch
mid-to-l full launch thereaft head-start japan repres one
under-appreci part growth stori given grow clinical/
real-world evid support ul bph therapi coupl sheer size
opportun urologist estim annual
clinic data aua least support lead versu
competit could lead upsid
clinic data front present find sever real-world outcom
sexual dysfunct studi upcom aua confer chicago may
signific among studi data real world outcom studi
show data patient treat ul across sever na australia site
suspect show find similar pivot lift clinic trial
benchmark includ improv ipp intern prostat symptom score
improv qmax peak urinari flow rate improv qualiti life
measur low rate sexual dysfunct ul versu average surgic
treatment low re-surg intervent rate ul studi includ
acut urinari retent studi show patient catheter-fre
within improv qualiti measur prostat cancer
studi show ul obscur mri diagnost high-risk high read
bottom line ul us uptak gain momentum clinic evid
support wider-scal use come set market entri japan within reach
growth franchis enough driver keep overal organ growth
upper-end near-term lrp target
pleas see import disclosur inform page report
